Lipella Pharmaceuticals Inc
LIPO2.360USD
-0.345-12.75%
Market hours （ET）Quotes delayed by 15 min
6.02MMarket Cap
LossP/E TTM
More Details of Lipella Pharmaceuticals Inc Company
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.
Company Info
Ticker SymbolLIPO
Company nameLipella Pharmaceuticals Inc
IPO dateDec 20, 2022
CEODr. Jonathan H Kaufman, Ph.D.
Number of employees5
Security typeOrdinary Share
Fiscal year-endDec 20
Address400 N Lexington St Ste LL103
CityPITTSBURGH
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code15208
Phone14129010315
Websitehttps://lipella.com/
Ticker SymbolLIPO
IPO dateDec 20, 2022
CEODr. Jonathan H Kaufman, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan H Kaufman, Ph.D.
Dr. Jonathan H Kaufman, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
112.35K
--
Dr. Micheal B. Chancellor
Dr. Micheal B. Chancellor
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Byeong (Christopher) Kim, Ph.D.
Dr. Byeong (Christopher) Kim, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Birder, Ph.D.
Dr. Lori A. Birder, Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Johnston, CPA
Mr. Douglas Johnston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Naoki Yoshimura, M.D., Ph.D.
Dr. Naoki Yoshimura, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Chuck Harbey
Mr. Chuck Harbey
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Cohen
Mr. Daniel Cohen
Independent Director
Independent Director
--
--
Mr. Ryan Pruchnic
Mr. Ryan Pruchnic
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan H Kaufman, Ph.D.
Dr. Jonathan H Kaufman, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
112.35K
--
Dr. Micheal B. Chancellor
Dr. Micheal B. Chancellor
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Byeong (Christopher) Kim, Ph.D.
Dr. Byeong (Christopher) Kim, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Birder, Ph.D.
Dr. Lori A. Birder, Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Johnston, CPA
Mr. Douglas Johnston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Naoki Yoshimura, M.D., Ph.D.
Dr. Naoki Yoshimura, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Kaufman (Jonathan H)
2.51%
Chancellor (Michael B.)
2.46%
Huang (Leaf)
1.55%
Sabby Management, LLC
1.35%
Tower Research Capital LLC
0.06%
Other
92.06%
Shareholders
Shareholders
Proportion
Kaufman (Jonathan H)
2.51%
Chancellor (Michael B.)
2.46%
Huang (Leaf)
1.55%
Sabby Management, LLC
1.35%
Tower Research Capital LLC
0.06%
Other
92.06%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.52%
Investment Advisor/Hedge Fund
1.35%
Hedge Fund
0.06%
Other
92.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
17
354.66K
7.94%
+95.32K
2025Q1
17
354.67K
11.68%
+95.33K
2024Q4
18
368.12K
30.45%
+2.26K
2024Q3
16
304.96K
29.23%
-126.37K
2024Q2
16
428.52K
49.20%
+108.86K
2024Q1
16
431.88K
52.07%
+138.44K
2023Q4
14
329.34K
44.74%
+70.35K
2023Q3
12
252.11K
34.85%
+66.33K
2023Q2
13
302.02K
42.06%
+116.08K
2023Q1
12
303.82K
42.31%
+124.35K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Kaufman (Jonathan H)
112.35K
2.51%
-4.00
-0.00%
Apr 09, 2025
Chancellor (Michael B.)
109.70K
2.46%
--
--
Apr 09, 2025
Huang (Leaf)
69.44K
1.55%
+60.76K
+700.03%
Mar 31, 2025
Sabby Management, LLC
60.33K
1.35%
+60.33K
--
Dec 31, 2024
Tower Research Capital LLC
2.71K
0.06%
+2.71K
--
Mar 31, 2025
MAI Capital Management, LLC
125.00
0%
--
--
Mar 31, 2025
BofA Global Research (US)
7.00
0%
--
--
Mar 31, 2025
Virtu Americas LLC
--
0%
-13.31K
-100.00%
Mar 31, 2025
HRT Financial LP
--
0%
-2.20K
-100.00%
Dec 31, 2024
Geode Capital Management, L.L.C.
--
0%
-3.11K
-100.00%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Date
Type
Ratio
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
